Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – November 12, 2025 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://oklahoma.zoom.us/webinar/register/WN_B7-m8jKcQWaA9HEiV7QRQA
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 928 6649 0447
Passcode: 80744869

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. October 8, 2025 DUR Board Meeting Minutes
   B. October 8, 2025 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. Haymore, Chairman:

4. **Action Item – Approval of 2026 DUR Board Meeting Dates – See Appendix B**
   A. 2026 DUR Board Meeting Dates

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

5. **Update on Medication Coverage Authorization Unit – See Appendix C**
   A. Pharmacy Help Desk Activity for October 2025
   B. Medication Coverage Activity for October 2025

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

6. **Hepatitis C Program Update – See Appendix D**
   A. Background
   B. Results of Claims Analysis
   C. Conclusions

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

7. **Action Item – Vote to Prior Authorize Eliquis® (Apixaban) Tablet for Oral Suspension and Eliquis® Sprinkle (Apixaban) Capsule for Oral Suspension and Update the Approval Criteria for the Anticoagulants and Platelet Aggregation Inhibitors – See Appendix E**
   A. Market News and Updates
   B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

8. **Action Item – Vote to Prior Authorize Avtozma® (Tocilizumab-anoh), Imuldosa® (Ustekinumab-srlf), Otezla XR™ [Apremilast Extended-Release (ER)], Starjemza™ (Ustekinumab-hmny), Steqeyma® (Ustekinumab-stba), and Yesintek™ (Ustekinumab-kfce) and Update the Approval Criteria for the Targeted Immunomodulator Agents – See Appendix F**
   A. Market News and Updates
   B. Cost Comparison: Currently Available Subcutaneous (Sub-Q) Ustekinumab Products
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

9. **Annual Review of Multiple Myeloma Medications and 30-Day Notice to Prior Authorize Boruzu® (Bortezomib) and Lynozyfic™ (Linvoseltamab-gcpt) – See Appendix G**
   A. Current Prior Authorization Criteria
   B. Utilization of Multiple Myeloma Medications
   C. Prior Authorization of Multiple Myeloma Medications
   D. Market News and Updates
   E. Lynozyfic™ (Linvoseltamab-gcpt) Product Summary
   F. Cost Comparison: Bortezomib Products
   G. College of Pharmacy Recommendations
   H. Utilization Details of Multiple Myeloma Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

10. **Annual Review of Bone Density Regulators and 30-Day Notice to Prior Authorize Bildyos® (Denosumab-nxxp), Bilprevda® (Denosumab-nxxp), Bomyntra® (Denosumab-bnht), Conexxence® (Denosumab-bnht), Osenvelt® (Denosumab-bmwo), and Stoboclo® (Denosumab-bmwo) – See Appendix H**
    A. Current Prior Authorization Criteria
    B. Utilization of Bone Density Regulators
    C. Prior Authorization of Bone Density Regulators
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Bone Density Regulators

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

11. **30-Day Notice to Prior Authorize Forzinity™ (Elamipretide) – See Appendix I**
    A. Introduction
    B. Forzinity™ (Elamipretide) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

12. **Annual Review of Amino Acid Disorder Medications and 30-Day Notice to Prior Authorize Harliku™ (Nitisinone), Orfadin® (Nitisone), Nityr® (Nitisinone), and Sephience™ (Sepiapterin) – See Appendix J**
    A. Current Prior Authorization Criteria
    B. Utilization of Amino Acid Disorder Medications
    C. Prior Authorization of Amino Acid Disorder Medications
    D. Market News and Updates
    E. Product Summaries
    F. Cost Comparison: Phenylketonuria (PKU) Products
    G. College of Pharmacy Recommendations
    H. Utilization Details of Amino Acid Disorder Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

13. **30-Day Notice to Prior Authorize Brinsupri™ (Brensocatib) – See Appendix K**
    A. Introduction
    B. Brinsupri™ (Brensocatib) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

14. **Annual Review of Atopic Dermatitis (AD) Medications and 30-Day Notice to Prior Authorize Anzupgo® (Delgocitinib 2% Cream) – See Appendix L**
    A. Current Prior Authorization Criteria
    B. Utilization of AD Medications
    C. Prior Authorization of AD Medications
    D. Market News and Updates
    E. Anzupgo® (Delgocitinib 2% Cream) Product Summary
    F. Cost Comparisons
    G. College of Pharmacy Recommendations
    H. Utilization Details of AD Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

15. **Annual Review of Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications and 30-Day Notice to Prior Authorize Omlyclo® (Omalizumab-igec) – See Appendix M**
    A. Current Prior Authorization Criteria
    B. Utilization of Asthma and COPD Maintenance Medications

C. Prior Authorization of Asthma and COPD Maintenance Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Asthma and COPD Maintenance Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

16. 60-Day Notice to Prior Authorize Andembry® (Garadacimab-gxii), Dawnzera™ (Donidalorsen), and Ekterly® (Sebetralstat) and Create a Product Based Prior Authorization (PBPA) Category for the Hereditary Angioedema (HAE) Medications – See Appendix N

A. Current Prior Authorization Criteria
B. Market News and Updates
C. Product Summaries
D. Estimation of Savings
E. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

17. 30-Day Notice to Prior Authorize Rhapsido® (Remibrutinib) – See Appendix O

A. Introduction
B. Rhapsido® (Remibrutinib) Product Summary
C. College of Pharmacy Recommendations

Non-presentation items reviewed by Dr. Moss, Dr. Haymore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Non-presentation items reviewed by Dr. Adams, Dr. Haymore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

A. Antidepressants
B. Complement Inhibitors and Miscellaneous Immunomodulatory Agents
C. Immune Globulin Intravenous and Subcutaneous Products
D. Lysosomal Storage Disease Medications
E. Skin Cancer Medications
F. Thrombocytopenia Medications

*Future product and class reviews subject to change.

Items to be presented by Dr. Haymore, Chairman:

20. Action Item – Nomination and Approval of DUR Board Officers

A. Nominations and Approval of DUR Board Chair and Vice Chair

21. Action Item – Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans. SoonerSelect PA data only includes medications billed as pharmacy claims (NDC) and does not include those billed as medical claims (HCPCS), where applicable.